Go to content
UR Home

Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009

Schlingensiepen, Karl-Hermann, Schlingensiepen, Reimar, Steinbrecher, Andreas, Hau, Peter, Bogdahn, Ulrich, Fischer-Blass, Birgit and Jachimczak, Piotr (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine & growth factor reviews 17 (1-2), pp. 129-139.

Download (903kB) - Repository staff only
Date of publication of this fulltext: 05 Aug 2009 13:24

at publisher (via DOI)

at PubMed

Other URL: http://dx.doi.org/10.1016/j.cytogfr.2005.09.002


TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta2 by the antisense ...


Export bibliographical data

Item type:Article
Institutions:Medicine > Lehrstuhl für Neurologie
Identification Number:
16377233PubMed ID
Keywords:TGF-β; High-grade gliomas; Pancreatic carcinoma; Malignant melanoma; Antisense oligodeoxynucleotides
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Unknown
Item ID:805
Owner only: item control page


Downloads per month over past year

  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons